827-33-8 Usage
General Description
4-bromo-5-chloro-2-nitrophenylamine is a chemical compound with the molecular formula C6H4BrClN2O2. It is an aromatic amine that contains a nitro group and halogen substituents. 4-bromo-5-chloro-2-nitrophenylamine is widely used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmacologically active compounds. It is also used as an intermediate in the production of dyes and agricultural chemicals. 4-bromo-5-chloro-2-nitrophenylamine is a yellow to brown crystalline solid that is moderately soluble in organic solvents and has a melting point of around 140-145°C. It is important to handle and store this compound with proper safety precautions, as it may be harmful if ingested, inhaled, or in contact with skin.
Check Digit Verification of cas no
The CAS Registry Mumber 827-33-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,2 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 827-33:
(5*8)+(4*2)+(3*7)+(2*3)+(1*3)=78
78 % 10 = 8
So 827-33-8 is a valid CAS Registry Number.
827-33-8Relevant articles and documents
PYRAZOLES AS MODULATORS OF HEMOGLOBIN
-
Page/Page column 140; 141, (2020/06/19)
The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula
HETERO-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME
-
Paragraph 0143-0146, (2018/07/28)
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting device comprising the same. The heterocyclic compound may be used as a material of an organic material layer of an organic light e
SERINE/THREONINE PAK1 INHIBITORS
-
Page/Page column 161-162, (2013/03/26)
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.